TREAT PTSD TRICARE Act
- Sponsor
- Rep. Perry, Scott [R-PA-10]
- Committees
- Armed Services Committee (primary)
- Last action
- May 12, 2026
Bottom line
This bill mandates the provision of stellate ganglion block therapy for active and reserve service members with PTSD under TRICARE and requires its formal inclusion in official clinical guidelines.
What it actually does
This bill directs the Secretary of Defense to furnish stellate ganglion block (SGB) to members of the Armed Forces, including reserve components, who are enrolled in the TRICARE program, have been diagnosed with post-traumatic stress disorder (PTSD), and elect to receive the treatment after being informed of its risks and benefits. It also mandates an update to the VA/DOD Clinical Practice Guideline for PTSD to include SGB as a therapy option and provide information on its clinical indicators and contraindicators.
Proponents argue
Supporters argue that SGB is a promising treatment for PTSD, offering rapid and sustained relief for some individuals, and making it accessible to service members could significantly improve their quality of life and reduce the burden of PTSD within the military community. They emphasize the importance of providing diverse and effective treatment options, especially for those who may not respond to traditional therapies.
Opponents contend
Critics might raise concerns about mandating a specific medical procedure through legislation, arguing that treatment decisions should remain solely at the discretion of medical professionals based on evolving evidence and individual patient needs, rather than being legislated. They might also question the long-term efficacy and cost-effectiveness of SGB compared to other established treatments, or potential resource allocation implications for the Department of Defense.
The bill is very short and clearly written, making it highly accessible for readers to understand its provisions quickly and evaluate its core intent.
Section 2(a), inserting new section 1074p into Chapter 55 of title 10, United States Code.
Mandatory Provision of Stellate Ganglion Block for Service Members with PTSD
This provision requires the Secretary of Defense to provide stellate ganglion block (SGB) to any active or reserve service member who is enrolled in TRICARE, has a diagnosed case of PTSD, and chooses to receive the treatment after a qualified healthcare provider has informed them of its potential risks and benefits. The treatment can be administered either at Department of Defense medical facilities or by qualified healthcare providers participating in a TRICARE health insurance program.
Supporters argue
Supporters argue this provision ensures that service members suffering from PTSD have access to a potentially life-changing therapy that has shown promising results in clinical studies for reducing PTSD symptoms. They contend it empowers service members with more treatment choices and addresses a critical mental health need within the military, potentially improving readiness and retention.
Critics contend
Critics might argue that mandating a specific medical treatment through legislation could interfere with clinical autonomy and the evidence-based practice of medicine. They may suggest that such decisions are best left to medical experts and existing DoD/VA processes for evaluating and integrating new therapies, rather than being legislated, to avoid premature adoption or unintended consequences.
Tradeoffs
The provision balances the desire to provide innovative PTSD treatments to service members with concerns about legislative overreach into medical practice and potential resource allocation challenges for a therapy that, while promising, may still be considered emerging by some medical bodies.
Section 2(b)
Update of Joint Clinical Practice Guideline for PTSD
This provision requires the Secretary of Defense to update the existing VA/DOD Clinical Practice Guideline for the Management of PTSD within 180 days of the bill's enactment. The updated guideline must explicitly reflect the availability of stellate ganglion block as a therapy option and include comprehensive information on its clinical indicators (when it's appropriate) and contraindicators (when it should not be used). The Secretary is also required to notify congressional defense committees once the guideline has been updated.